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Background: Chronic obstructive pulmonary disease (COPD) remains a major cause of morbidity and mortality. 
Present-day diagnostic criteria are largely based solely on spirometric criteria. Accumulating evidence has 
identiied a substantial number of individuals without spirometric evidence of COPD who sufer from respiratory 
symptoms and/or increased morbidity and mortality. There is a clear need for an expanded deinition of COPD 
that is linked to physiologic, structural (computed tomography [CT]) and clinical evidence of disease. Using 
data from the COPD Genetic Epidemiology study (COPDGene®), we hypothesized that an integrated approach 
that includes environmental exposure, clinical symptoms, chest CT imaging and spirometry better deines 
disease and captures the likelihood of progression of respiratory obstruction and mortality.
Methods: Four key disease characteristics – environmental exposure (cigarette smoking), clinical symptoms 
(dyspnea and/or chronic bronchitis), chest CT imaging abnormalities (emphysema, gas trapping and/or airway 
wall thickening), and abnormal spirometry – were evaluated in a group of 8784 current and former smokers who 
were participants in COPDGene® Phase 1. Using these 4 disease characteristics, 8 categories of participants 
were identiied and evaluated for odds of spirometric disease progression (FEV1 > 350 ml loss over 5 years), and 
the hazard ratio for all-cause mortality was examined.
Results: Using smokers without symptoms, CT imaging abnormalities or airlow obstruction as the reference 
population, individuals were classiied as Possible COPD, Probable COPD and Deinite COPD. Current Global 
initiative for obstructive Lung Disease (GOLD) criteria would diagnose 4062 (46%) of the 8784 study participants 
with COPD. The proposed COPDGene® 2019 diagnostic criteria would add an additional 3144 participants. 
Under the new criteria, 82% of the 8784 study participants would be diagnosed with Possible, Probable or 
Deinite COPD. These COPD groups showed increased risk of disease progression and mortality. Mortality 
increased in patients as the number of their COPD characteristics increased, with a maximum hazard ratio for 
all cause-mortality of 5.18 (95% conidence interval [CI]: 4.15–6.48) in those with all 4 disease characteristics.
Conclusions: A substantial portion of smokers with respiratory symptoms and imaging abnormalities do 
not manifest spirometric obstruction as deined by population normals. These individuals are at signiicant 
risk of death and spirometric disease progression. We propose to redeine the diagnosis of COPD through an 
integrated approach using environmental exposure, clinical symptoms, CT imaging and spirometric criteria. 
These expanded criteria ofer the potential to stimulate both current and future interventions that could slow or 
halt disease progression in patients before disability or irreversible lung structural changes develop.
Abbreviations: chronic obstructive pulmonary disease, COPD; computed tomography, CT; COPD Genetic Epidemiology study, 
COPDGene®; Global initiative for chronic Obstructive Lung Disease, GOLD; conidence interval, CI; forced expiratory volume in 1 second, 
FEV1; forced vital capacity, FVC; preserved ratio-impaired spirometry, PRISm; modiied Medical Research Council, mMRC; low attenuation 
area, LAA; Hounsield units, HU; square root of airway wall area for a standardized airway of 10 mm internal, Pi10; medical outcomes study 
short form 36, MOS SF 36; mental component score, MCS; physical component score, PCS; longitudinal follow-up, LFU; standard deviation, 
SD; odds ratio, OR; hazard ratio, HR; St George’s Respiratory Questionnaire, SGRQ
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Chronic obstructive pulmonary disease (COPD) is 
a heterogeneous, chronic inlammatory process of 
the airways often involving destruction of adjacent 
alveoli and vasculature. Symptoms range from 
chronic productive cough to debilitating dyspnea. 
Introduction 
Disease trajectory can vary from years of stability 
to devastating acute exacerbations and respiratory 
failure. COPD remains a major burden on patients, 
their caregivers and the health care system.1  It is 
the 4th leading cause of death in the United States2 
and is the 8th leading cause of disability as measured 
by disability-adjusted life years.3  An understanding 
of this disorder dates back centuries,4 including 
appreciation of the emphysematous5 and chronic 
bronchitic components.6 The diagnostic approach to 
this disorder was revolutionized with the invention 
of the spirometer7 and timed measurement of forced 
exhalation of expired air.8-10  The foundations of our 
current diagnostic approaches date to decades-old 
landmark meetings which established clinical criteria 
for bronchitis and emphysema11,12; the term COPD 
was irst coined at the 9th Aspen Lung Conference.13 
Based on this historical background, patients 
are currently diagnosed by spirometry, a history of 
exposure (smoking or other environmental factors) 
and respiratory symptoms at the time of presentation. 
The Global initiative for chronic Obstructive 
Lung Disease (GOLD) has advocated for a post-
bronchodilator forced expiratory volume in 1 second 
(FEV1)  to forced vital capacity (FVC) ratio less than 
0.70 as the key diagnostic criterion14; this feature has 
remained controversial.15-22 Disease severity has been 
characterized using physiologic and, more recently, 
clinical parameters.23,24 Despite these approaches, 
it has become evident that disease trajectory can 
vary from years of stability to devastating acute 
exacerbations and respiratory failure.25,26 In addition, 
several groups have demonstrated that many smokers 
without traditional spirometric obstruction experience 
symptoms and structural changes (emphysema 
and airway wall thickening) similar to those seen 
in spirometrically diagnosed COPD.15,16 Disease 
progression data has shown that smokers who progress 
to spirometry-defined COPD typically progress 
through 1 of 3 pathways:  (1) an airway-disease 
predominant pathway that progresses through the 
preserved ratio- impaired spirometry ([PRISm], low 
FEV1 with normal FEV1/FVC) phase27,28  into GOLD 
stages 2-4; (2) an emphysematous-predominant 
pathway that primarily progresses through GOLD 
stage 1 into GOLD stages 2-4; and (3) a combination 
airway-emphysema pathway that progresses directly 
from GOLD 0 stage to GOLD stages 2-4.29 The 
totality of this data has raised signiicant concerns 
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The COPDGene® study recruited non-Hispanic 
whites and African Americans, aged 45-80, who were 
current or former smokers with a reported smoking 
history of at least 10 pack years.31  Participants were 
recruited across the spectrum of pulmonary function 
and included those previously classiied as having 
normal post-bronchodilator spirometry based on 
an FEV1 t 80% predicted and an FEV1/FVC ratio t 
0.70, GOLD stages 1-4 as well as PRISm spirometry 
(FEV1 < 80% predicted and FEV1/FVC ratio t 0.70). 
Individuals with known interstitial lung disease 
or initial computed tomography (CT) scans that 
suggested either interstitial lung disease or difuse 
bronchiectasis were excluded from the current analyses 
(see online supplement Table S1). The COPDGene® 
study was approved by the institutional review board 
at each COPDGene® center, and all participants 
provided written informed consent. In addition, all 
protocols were approved by the institutional review 
boards at National Jewish Health and the University of 
Colorado-Denver. The COPDGene® study has 3 phases 
of participant assessment (i.e., baseline, 5-year and 
current ongoing 10-year visits) and began in 2007.
Phase 1 COPDGene® enrollment occurred between 
2007-2012, and participants were invited to return for 
a follow-up evaluation after 5 years that was termed 
Phase 2. At both visits, pre- and post-bronchodilator 
spirometry was performed using the same spirometers 
and methodology. Change in FEV1 was calculated as 
evidence of disease progression beyond the expected 
normal age-related loss (i.e., > 350 ml loss over 5 
years).
Patients with an FEV1 t 80% predicted and an 
FEV1/FVC ratio t 0.70 are often referred to as “normal 
spirometry” based on population standards. In a 5-year 
follow-up of these participants in the COPDGene® 
cohort, signiicant evidence of the development of 
airlow obstruction in individuals (i.e., signiicant 
loss of FEV1 where the FEV1 does not drop below the 
population lower limit of normal) has been identiied, 
and we therefore use the term GOLD 0 rather than 
“normal spirometry” to deine this group.15  The term 
PRISm (GOLD Unclassiied) rather than restrictive 
spirometry has been used to deine the group having 
an FEV1 < 80% predicted and an FEV1/FVC ratio t 
0.70.27,28 
Participants were characterized using chest CT 
scans, spirometry (before and after bronchodilator 
inhalation), and patient-reported respiratory 
symptoms. The COPDGene® Phase 1 visit included 
10,263 smokers. Those with bronchiectasis (n=30), 
interstitial lung disease (n=35), or who had undergone 
a lung transplant or lung volume reduction surgery 
(n=20) during follow-up were excluded from these 
analyses. An additional 1394 participants were 
excluded because they lacked data on 1 or more of 
the disease assessments (predominately excluded for 
lacking quantiiable CT data), and therefore, could 
not be fully classiied. The inal sample for analysis 
included 8784 participants. 
We tested novel criteria to identify COPD and 
evaluated these criteria for impact on disease 
progression and mortality. We considered 4 
characteristics of disease linked to COPD: exposure, 
structural lung changes as quantitatively assessed 
by chest CT, respiratory symptoms, and spirometric 
evidence of impairment (Figure 1). Exposure: In 
COPDGene® the minimum exposure was a 10 pack-year 
smoking history. Symptoms: Self-report of dyspnea  
2 on the modiied Medical Research Council (mMRC) 
dyspnea score32 and/or chronic bronchitis (self-
reported chronic cough and phlegm). CT Structural 
Abnormality: Deined as  5% emphysema (low 
attenuation area [LAA] -950 Hounsield units [HU]) 
Methods
regarding the optimal approach to taxonomic 
classiication of COPD.30 
We propose redeining the diagnostic criteria for 
COPD recognizing the spectrum of disease, including 
exposure, symptoms, spirometric indings, and image-
based assessment of structural abnormalities. We 
present an analysis of baseline phenotyping and 5-year 
longitudinal progression of a large cohort of current 
and former heavy smokers enrolled in the COPD 
Genetic Epidemiology study (COPDGene®).31  Our 
analysis is based on the hypothesis that spirometric 
criteria alone are insuicient to characterize smoking-
related disease burden. We propose a new diagnostic 
classiication to: (1) identify individuals who are at 
higher risk of disease progression and mortality;
(2) inform patients early in the course of the disease; 
(3) identify patients who may beneit from therapy; 
and (4) test new therapies to slow or halt disease 
progression in patients before disability or irreversible 
lung structural changes develop.
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on inspiratory CT, and/or   gas-trapping (LAA 
-856 HU) on expiratory CT, and/or Pi10 (Square root 
of airway wall area for a standardized airway of 10 mm 
internal perimeter)  2.5 mm. Spirometry: Patients 
with abnormal spirometric values (FEV1 < 80% 
predicted and/or FEV1/FVC < 0.70) were classiied as 
having spirometric evidence of disease.21 
Using the 4 disease characteristics, participants 
were classiied into 8 mutually exclusive categories. 
The 8 disease categories include all combinations of 
the 4 disease characteristics, with exposure considered 
positive in all due to the design of the COPDGene® 
study (Table 1). Thus, this proposed classiication 
system would apply to current and former smokers. 
COPDGene® required a history of at least 10 pack 
years of cigarette smoking, and the mean smoking 
history ranged from 35 to 54 pack years (Table 2).
Assessment of Change in FEV1
Progression of loss of FEV1 was assessed in 4925 
participants who returned for a Phase 2 visit that 
was scheduled approximately 5 years following the 
Phase 1 visit. The number of participants returning 
for a Phase 2 visit is shown for each Category (AH) 
in online supplement Tables S2AS2H, which also 
compares the demographics, clinical, physiologic and 
radiographic indings at Phase 1, of the participants 
who returned for a Phase 2 visit with those who did not 
return for a Phase 2 visit, and those who died without 
a Phase 2 visit.
Mortality Assessment
COPDGene® established a structure for monitoring 
longitudinal outcomes and events, including death, that 
was termed longitudinal follow-up (LFU).33  This was 
a multilayered process for participant contact and data 
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collection that occurred every 6 months and included 
email contacts with website data entry, or automated 
phone calls with integrated data entry.33  If automated 
contacts were unsuccessful, direct coordinator calls 
to the participant were employed, and as necessary, 
to their secondary contacts. This LFU program was 
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Results
Baseline Characterization
We classiied participants into 8 diferent categories 
of smokers who spanned the spectrum of spirometric 
disease severity from normal to advanced abnormality. 
All categories had a heavy smoking exposure (Table 
2). 
The following 8 categories were deined (note 
all groups are positive for exposure; i.e., cigarette 
smoking): 
Exposure only: Reference Category
CT abnormal (emphysema, airway wall thickness 
or gas trapping)
Symptoms (dyspnea or chronic bronchitis)
Spirometry abnormal (low FEV1 or FEV1/FVC
ratio)
Symptoms plus CT abnormal 
Symptoms plus spirometry abnormal 
Spirometry abnormal plus CT abnormal 
Symptoms plus spirometry abnormal plus CT 
abnormal 
A.
B.
C.
D.
E.
F.
G.
H.
initiated during Phase 1 in 2009; contacts were made 
at 6-month intervals and are ongoing. 
The outcomes and events tracked through the 
LFU program included: vital status (with follow-
up determination of death, if no contact), any 
exacerbation and severe exacerbation (requiring 
emergency department visit or hospitalization), 
pneumonia, hospitalizations and various other 
comorbid disease events. Date of death was ascertained 
from a combination of next of kin reports, medical 
records, death certiicates, and published obituaries. 
Supplemental searching of the Social Security Death 
Index was carried out to augment documented deaths 
on these subsets of the cohort but was limited by access 
to social security numbers (last Social Security Death 
Index search was November 2016). A last contact date 
(from LFU or participant tracking) was recorded for 
those participants not known to be deceased and used 
to calculate the time interval from study entry. The 
cause of death was adjudicated as described by Young 
et al.34 
The current mortality dataset (established October 
2018) included 10,263 participants. There were 1795 
deaths recorded, with a mean follow-up time of 83 ± 
31 (standard deviation [SD]) months, range 0–129 
months. Mortality assessment for Categories AH 
involved 8784 participants for which there were 1516 
deaths (mean follow-up time was 86 ± 29 [SD] months, 
range 0–129 months).
Statistical Analysis
We initially evaluated baseline demographics, 
spirometry, respiratory symptoms, and CT metrics of 
the cohort by COPD diagnosis category. We evaluated 
spirometric progression using logistic regression 
and all-cause mortality using Cox proportional 
hazards modeling. Models were run using 4 disease 
characteristics within the 8 categories as deined in 
Figure 2 . The Reference Category remained the same 
in all models: asymptomatic smokers without evidence 
of CT abnormality and normal spirometry (Category 
A, Figure 1). The logistic regression model calculating 
the odds of abnormal spirometric progression (FEV1 
loss > 350 ml over 5 years) was adjusted for participant 
age at study entry, sex, race, current smoking, pack 
years, and baseline FEV1 post-bronchodilator. Cox 
regression models were used to estimate hazard ratios 
for all-cause mortality. Cox models were implicitly 
adjusted for age by using age as the underlying 
timescale. The Cox regression models for all-cause 
mortality were additionally adjusted for sex, race, pack 
years and current smoking. Conidence intervals (CI) 
of 95% are provided. A limitation of the statistical 
analysis is that adjustments were not made for missing 
data. The primary cause for missing participants was 
the absence of CT imaging for expiratory CT scans. 
This type of missing data is deemed not to be related 
to disease or outcome and is not likely to bias the 
statistical analysis. Participants lost due to death are 
most important in analysis of participants meeting 
GOLD 3 or 4 criteria.
Participants were invited to return for Phase 2 visits 
5 years after initial enrollment. These visits occurred 
between 20122017. Of the 8784 participants 
included in the current analysis, 4925 completed a 
Phase 2 visit. These are the participants who were used 
to compute the odds ratio (OR) for change in FEV1 
(Figure 2). The missing participants from this analysis 
included 3859 participants, of which 1178 died prior 
to the Phase 2 visit and 2681 were either lost to follow-
up or declined to return. Online supplement Tables 
S2A–S2H give the characteristics of those participants 
in each disease category who returned for Phase 2 
visits and for those who did not return.
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The distribution of GOLD stages across the proposed 
COPDGene® 2019 categories is shown in Table  3, and 
baseline demographics can be found in Table 2. 
     
Category A (Reference Category, n=1575) 
exhibited the least spirometric abnormality with 
average FEV1% predicted of 98% and average FEV1/
FVC of 0.80. They exhibited little to no evidence 
of disease on chest CT, and they have the lowest St 
George’s Respiratory Questionnaire (SGRQ) total 
score (8.7, SD 9.7) of the 8 categories.
Category B (CT abnormal, n=988) also had similar 
spirometry (average FEV1% predicted 98%, average 
FEV1/FVC 0.77) and similar SGRQ to the Reference 
Category (9.1, SD 10.6). Average gas-trapping (at 
-856 HU on expiratory images) in this category was 
17.65%, average emphysema was 3.94%, and average 
Pi10 was 2.12 mm.
  
Category C (Symptoms, n=630) had a worse 
quality of life with a higher SGRQ total score (34.0, SD 
18.6) but similar spirometry to the Reference Category 
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(average FEV1% predicted 96.8%, average FEV1/FVC 
0.80). 
Category D (Spirometry abnormal, n=477) was 
largely composed of participants classiied as PRISm 
or GOLD 12 (average FEV1% predicted 77.2%, 
average FEV1/FVC 0.72). Category D had a slightly 
higher SGRQ total score (11.5, SD 10.9). CT metrics 
were similar to the Reference Category, with a slight 
increase in airway wall thickness (Pi10).
Category E (Symptoms plus CT abnormal, n=472) 
had slightly lower spirometric values (average FEV1% 
predicted 95%, average FEV1/FVC 0.78). Similar to 
Category C, Category E had an elevated SGRQ score 
(35.7, SD 18.8). Gas-trapping was slightly lower (mean 
14.3%) and the Pi10 was slightly higher (2.44 mm, SD 
0.62) than Category B. 
Category F (Symptoms plus spirometry abnormal, 
n=325) was largely clustered in the less severe 
spirometric range, with 58.8% PRISm, 16.0% GOLD 
1, and 24% GOLD 2. Approximately 1% would have 
been classiied as GOLD 3, and these 4 participants 
were very close to the GOLD 2 range. Mean FEV1% 
predicted was 73.9%, mean FEV1/FVC was 0.72, and 
the mean SGRQ Total score was 38.4 (SD 18.6). 
Category G (Spirometry abnormal plus CT 
abnormal, n=1442) resulted in a distribution of 
participants broadly across the spirometric spectrum 
(mean FEV1% predicted 70.2%, mean FEV1/FVC 0.62) 
and included participants in all GOLD classiications. 
However, this category was less symptomatic with a 
lower SGRQ total score (16.0, SD 13.3) than Category 
F. Structural damage on CT imaging was extensive, 
with mean 27.6% gas-trapping, 7.5% emphysema, and 
Pi10 of 2.53 mm (SD 0.58). 
    
Category H (Symptoms plus spirometry abnormal 
plus CT abnormal, n=2875) was clearly the 
most severely afected, with abnormal spirometry 
(mean FEV1% predicted 50.9%, mean FEV1/FVC 
0.51), extensive CT abnormalities, and symptoms. 
Participants in this category had mean gas-trapping of 
38.1%, 13.5% emphysema, and Pi10 of 2.81 mm (SD 
0.58). They had the highest SGRQ total score (48.2, SD 
18.6). 
Disease Progression
A summary of the OR for progression and hazard 
ratio (HR) for mortality is shown in Figure 2. 
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Table 4  shows the OR for progression and HR for 
mortality when the participants were grouped by 
their classiication into categories of Possible COPD 
(2 disease characteristics), Probable COPD (3 
disease characteristics) or Deinite COPD (4 disease 
characteristics). Forest plots with the 8 categories and 
their corresponding OR for disease progression, and 
separately with their HR for all-cause mortality are 
shown in Figure 3.  
     
Category B (CT abnormal): The OR of FEV1 
progression in the category with only CT abnormalities 
was 1.31 (95% CI: 1.04–1.65) compared to the 
reference. There was no evidence of increased all-
cause mortality (HR 1.05, 95% CI: 0.76–1.44). Similar 
to the Reference Category, Category B did not report 
many severe exacerbations (2% of participants had a 
hospitalization in the past year).
    
Category C (Symptoms): A total of 9% of Category 
C reported a severe COPD exacerbation within the past 
year, compared to 1% in the Reference Category, and 
had an increased OR of  > 350 ml reduction in FEV1 
over 5 years (OR 1.42, 95% CI: 1.07–1.88). Category 
C also had an increased HR for all-cause mortality 
(HR 1.55, 95% CI: 1.09–2.19) when compared to the 
Reference Category.
     
Category D (Spirometry abnormal): Compared 
to the Reference Category, there was no evidence of 
increased odds of disease progression based on FEV1 
change (OR 0.92, 95% CI: 0.64–1.30). However, there 
was evidence of an increased HR for all-cause mortality 
(HR 1.48, 95% CI: 1.03–2.12).
Category E (Symptoms plus CT abnormal): There 
was evidence for an increased OR of FEV1 decline (OR 
1.74, 95% CI: 1.28–2.36) and evidence for increased 
mortality (HR 1.90, 95% CI: 1.33–2.71) compared to 
the exposure-only category. This category had a high 
rate of severe exacerbations, with 13% of participants 
reporting a severe exacerbation in the past year. 
Category F (Symptoms plus spirometry abnormal): 
There was no evidence of an increased OR of FEV1 
decline in this category (OR 1.02, 95% CI: 0.66–1.60), 
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but there was an increased HR for mortality (HR 2.62, 
95% CI: 1.84–3.72).
Category G (Spirometry abnormal plus CT 
abnormal): The OR of FEV1 progression in this 
category was 2.11 (95% CI: 1.66–2.68) and the HR for 
all-cause mortality was 1.76 (95% CI: 1.36–2.27) when 
compared to the exposure only category. 
     
Category H (Symptoms plus spirometry abnormal 
plus CT abnormal): OR of spirometric progression 
was highest in this category (OR 2.82, 95% CI: 2.18–
3.66) and mortality was 5 times higher than in the 
Reference Category (HR 5.18, 95% CI: 4.15–6.48). 
Approximately 11% of this category reported a severe 
exacerbation within the past year.
Intensity of smoking (pack years) was not used 
to deine disease categories; however, pack years is 
strongly associated with disease severity, going from 
35.0 pack years in Category A to 53.7 pack years in 
Category H (Table 3). Current smoking status strongly 
correlates with symptoms. Categories C and E, selected 
by symptoms without spirometric abnormality, 
have high rates of current smoking (77% and 74%, 
respectively) and high incidence of exacerbations 
in the year prior to enrollment, while spirometrically 
abnormal categories without symptoms (D and 
G) have lower levels of current smoking (57% and 
47%, respectively) and report fewer exacerbations. 
Categories based on symptoms (C, E, F, H) also 
demonstrate lower 6-minute walk distance test results.
More disease manifestations were associated 
with greater risk of disease progression and higher 
mortality overall. CT imaging abnormalities and 
clinical symptoms alone were each associated with 
an increased risk of enhanced loss of FEV1 (OR 1.31, 
95% CI: 1.04–1.65 and OR 1.42, 95% CI: 1.07–1.88, 
respectively) (Figure 3). Symptoms alone were also 
associated with an increased HR for all-cause mortality 
of 1.55 (CI: 1.08–2.19). Interestingly, abnormal 
spirometry alone was not predictive of spirometric 
progression (OR 0.92, 95% CI: 0.64–1.30), although it 
was associated with a signiicant HR for mortality of 
1.48 (CI: 1.03–2.12).
Of the 3665 GOLD 0 participants in this analysis, 
2090 (57%) showed some combination of structural 
damage on CT or respiratory symptoms. Of the PRISm 
participants , the inclusion of FEV1 < 80% predicted as 
395 COPDGene® 2019: Redefining COPD Diagnosis
journal.copdfoundation.org   JCOPDF © 2019 Special Issue • 2019
For personal use only. Permission required for all other uses.
Discussion
COPD continues to present an increasing burden 
on patients and the health care system.1 Although 
therapeutic options exist to improve pulmonary 
function and symptoms, there are limited options 
to stop or slow disease progression. This, in part, 
relects the tremendous heterogeneity in disease 
manifestation and longitudinal disease course. 
Although the pathological nature of the disease has 
been appreciated for centuries, current diagnostic 
criteria rely on spirometric measures. Over the past 
several years, it has become evident that patients 
a spirometric criteria moved them into categories D, 
F, G, and H. Category E, representing patients without 
abnormal spirometry but exhibiting both structural 
abnormalities on CT scan and respiratory symptoms, 
had striking associations to disease progression (OR 
1.74, 95% CI: 1.28–2.36) and mortality (HR 1.9, 95% 
CI: 1.33–2.71) (Figure 2). Category F with abnormal 
spirometry and respiratory symptoms by comparison, 
was the smallest category, did not show signiicant 
progression but experienced increased mortality (HR 
2.62, 95% CI: 1.84–3.72) (Figure 2). More than half 
(59%) of these participants were PRISm (Table 3).
Clinical features of each category (Table 2) relect 
the selection process with categories based on 
imaging abnormalities (B, E, G, H) having greater 
emphysema, gas trapping, and airway disease. Those 
selected in part for spirometry abnormalities (D, F, 
G, H) have lower values for FEV1 and FEV1/FVC and 
those selected for symptoms have worse SGRQ scores 
and higher proportions of participants reporting 
signiicant dyspnea or chronic bronchitis. 
The number of positive categories appears to strongly 
impact the outcomes of spirometric progression 
and mortality (Table 4). One positive manifestation 
beyond exposure (Possible COPD) has an overall 
OR 1.26 (95% CI: 1.03–1.53) for progression, and 
overall HR 1.28 (95% CI: 0.99–1.66) for mortality. Two 
disease manifestations beyond exposure (Probable 
COPD) have an overall OR 1.88 (95% CI: 1.52–2.32) 
for progression and HR for mortality of 1.89 (95% CI: 
1.48–2.41), while 3 disease manifestations beyond 
exposure (Deinite COPD) has an OR for progression 
of 2.88 (95% CI: 2.23–3.71) and an HR for mortality of 
5.21 (95% CI: 4.17–6.52).
without spirometric abnormalities experience 
respiratory symptoms and acute exacerbation-like 
events.15,16 CT imaging in these individuals often 
demonstrates signiicant structural abnormalities. 
We tested the hypothesis that spirometric criteria 
alone are insuicient to characterize smoking-related 
disease burden. 
In a cohort of over 10,000 individuals who have an 
extensive history of cigarette smoking, careful baseline 
phenotyping and a 5-year longitudinal assessment 
were done. Using this data, we demonstrate:
(1) significant differences in physiological, 
symptomatic and CT structural imaging abnormalities 
despite similar cigarette smoke exposure; (2) the 
ability to characterize patients into mutually exclusive 
categories that deine the multidimensional nature 
of disease manifestation; and (3) the incremental 
inluence of these manifestations on traditional 
measures of disease progression, including lung 
function decline and all-cause mortality.
COPD is a heterogeneous disease in which each 
patient appears to display a unique set of disease 
manifestations. Our comprehensive analyses suggest 
that spirometry alone fails to capture and contextualize 
the extent of disease manifestation. For example, the 
classically used diagnostic criteria fail to diagnose 
those with early but symptomatic disease and do 
not consider individuals whose pattern of disease 
progression is that of a concurrent loss of both FEV1 
and FVC, resulting in maintenance of an FEV1/FVC 
ratio t 0.70. We deine these patients as having PRISm 
physiology, an important pathway of early disease 
progression.27,28,35,36 The COPDGene® 2019 criteria 
will diagnose COPD in a large number of individuals 
(heavy current and former smokers) who have an 
FEV1/FVC ratio t 0.7 and who would be located 
within the GOLD stage 0 and PRISm categories. The 
data in Figure 4  shows that adding COPDGene® 
2019 categories Probable and Deinite COPD would 
include an additional 1279 participants in the 
diagnosis of COPD, which is 14.6% of this population. 
Including Possible COPD under the COPDGene® 
2019 diagnostic criteria would add another 21.4% of 
the population or 1868 additional individuals to be 
diagnosed as COPD patients.
Our proposed categories would redeine the 
diagnosis by better capturing the spectrum of disease 
seen in COPD patients, including recognizing early 
onset of disease, identifying patterns of disease 
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progression, and better predicting morbidity and 
mortality. The Reference Category has relatively 
normal spirometry, little to no evidence of disease 
on chest CT scans, and the least impaired quality of 
life of the 8 categories. Category H, which exhibits 
abnormalities in all 4 disease characteristics, is 
the most burdened with severe airlow obstruction, 
extensive structural abnormalities on CT, respiratory 
symptoms, poor quality of life, reduced 6-minute walk 
distance results, and exacerbations. Importantly, these 
indings, in concert with the worst outcome for FEV1 
progression (OR 2.82, 95% CI: 2.18–3.66) and highest 
mortality (HR 5.18, 95% CI: 4.15–6.18), describe the 
impact of extensive, late-stage and likely irreversible 
COPD. However, the other categories (B through G) 
exhibit incremental impact of disease manifestations 
on outcomes, function and events. The observation 
that these manifestations are associated with late-
stage disease and also impact the outcomes of disease 
progression and mortality suggests strongly that they 
should be integrated into the diagnostic spectrum for 
COPD.
Patients with another established disease diagnosis 
that would explain their symptoms, CT indings or 
spirometric indings should be considered for exclusion 
from a diagnosis of COPD. For example, cardiovascular 
and musculoskeletal diseases are common causes for 
dyspnea or exercise limitation. Interstitial lung disease 
and obesity are common causes of PRISm physiology.
Increasing the population to be considered for 
inclusion within a COPD diagnosis makes sense 
biologically, as disease processes begin before 
physiologic compromise is suicient to satisfy a 
disease deinition based only on signiicant airway 
obstruction. Doing so can highlight individuals who 
should be targeted for disease modifying therapy, 
particularly early in the disease course. Increasing the 
population within the scope of COPD, however, will 
also increase the importance of personalized medicine. 
In this context, it is likely that individuals within GOLD 
0 and PRISm who are at risk for disease progression 
are mechanistically heterogeneous. Further studies to 
better delineate this heterogeneity will be essential for 
development and implementation of novel therapies.
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     Limitations to the COPDGene® 2019 criteria include 
that it currently applies only to individuals with a 
substantial smoking history. Substantial smoking was 
an entry criterion for COPDGene®. The COPDGene® 
2019 criteria do not consider comorbid conditions or 
the efects of current treatment. The analysis needs to be 
extended to include data from other cohorts assessing 
occupational exposures, environmental pollutant 
exposures and environmental biomass exposures. 
The COPDGene® cohort includes data from African 
American and non-Hispanic white participants and 
future studies will be needed to study other ethnicities. 
Both inspiratory and expiratory chest CT scans were 
obtained. Thus, measurements of -950 HU and -856 
HU were obtained at 2 diferent lung volumes. The 
thresholds used to deine emphysema, gas trapping 
and airway wall thickening were developed based on 
COPDGene® CT imaging protocols and the speciic 
software used for analyses; other CT protocols and 
analytical software may require diferent thresholds for 
these disease-related characteristics.
We propose that utilizing increases in the number 
of positive disease aspects (representing the number 
of disease manifestations in an individual) is a useful 
method for classiication allowing additional diagnoses 
of Possible COPD and Probable COPD to that of 
Deinite COPD. We demonstrate that incremental 
disease manifestations are associated with worse 
outcomes as relected by lung function decline and 
mortality. Current COPD diagnostic criteria fail to 
capture individuals with smoking-related disease 
who are at increased risk of progressive lung function 
loss and mortality. Deining individuals who are 
symptomatic but who do not yet show CT evidence of 
structural lung disease as Possible COPD will improve 
access to secondary prevention strategies such as 
aggressive eforts to stop smoking and interventions 
with pulmonary rehabilitation. An expanded deinition 
will also enable clinical development of potential 
disease-modifying therapies.
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